Zydus Lifesciences will acquire Assertio Holdings to strengthen its US specialty and oncology business presence.
Zydus Lifesciences, an Ahmedabad-based pharmaceutical company, has announced its definitive agreement to acquire Assertio Holdings, for approximately 166.4 million (around Rs 1,590 crore) in an all-cash deal. The acquisition will be executed through Zydus Worldwide DMCC, a subsidiary, which will acquire all outstanding shares of Assertio for 23.50 per share. This transaction is structured as a tender offer, to be followed by a merger for any remaining shares at the same price. The deal is anticipated to close in the second quarter of 2026, subject to customary closing conditions.
The primary motivation behind this acquisition is Zydus's strategic intent to bolster its specialty and oncology presence in the United States. Assertio is a commercial-stage pharmaceutical firm specializing in oncology supportive-care therapies, as well as neurology and pain management. The acquisition provides Zydus with an established specialty oncology commercial platform and the opportunity to leverage Assertio's focused commercial infrastructure and relationships with oncologists and specialty-care providers to expand its footprint in the US market.
A key asset in this acquisition is Rolvedon (eflapegrastim-xnst), a long-acting biologic approved by the US Food and Drug Administration (FDA). Rolvedon is used for the prevention of febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy. This novel biologic posted net sales of 68.2 million in 2025, an increase from 60.1 million in the previous year. Sharvil Patel, MD of Zydus Lifesciences, stated that Assertio brings a focused commercial platform and an approved oncology asset that aligns with Zydus’s long-term strategy of building differentiated, durable specialty businesses globally.
Economically, the all-cash deal represents a significant investment for Zydus. The offer price of 23.50 per share represents a substantial premium for Assertio shareholders: a 30.6% premium over Garda Therapeutics' initial 18.00 per share offer and a 7.8% premium over its revised $21.80 per share offer. It also reflects a 75.8% premium to Assertio's unaffected share price on March 20, 2026. Assertio's board deemed Zydus's proposal a "superior proposal" due to its pricing, execution certainty, and the absence of financing contingencies, ensuring direct recourse for Assertio in case of any breach.
This acquisition highlights a broader industry trend among Indian pharmaceutical companies to shift towards building branded specialty portfolios in regulated markets, moving beyond a sole reliance on traditional generic medicines. This strategy aims to secure products with longer exclusivity periods and differentiated formulations. For Zydus, this move is part of its ongoing efforts to expand its complex generics and specialty portfolio in the US and establish a direct commercial interface with specialists in key therapeutic areas. The company had previously armed itself with a Rs 5,000 crore enabling Qualified Institutional Placement (QIP), approved in FY26, which its management had consistently pitched as a strategic lever for sharpening its specialty footprint in the US through acquisitions.
